http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101171863-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-10 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5023 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-711 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2010-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101171863-B1 |
| titleOfInvention | A pharmaceutical composition for inhibiting cancer metastasis or inhibiting cancer metastasis comprising inhibitors of the expression or activity of the PRP4 protein, a novel cancer treatment target. |
| abstract | The present invention relates to a pharmaceutical composition for treating cancer or inhibiting cancer metastasis, which comprises a novel cancer therapeutic target, the expression or activity inhibitor of PRPF4 protein, as an active ingredient. Using a mining technique, a novel targeting anticancer candidate target was identified, and based on the gene expression pattern in the cancer cell line, an appropriate cancer cell line was selected and experimentally verified through the inhibition of the target candidate gene. , Overexpression in cancer tissues and cancer cells, such as lung cancer and breast cancer, inhibiting the growth, migration, invasion and metastasis of cancer cells by the inhibition of PRPF4 and induce apoptosis, confirming the possibility of PRPF4 as a target of a new anticancer agent , Inhibitors of the expression or activity of PRPF4 protein may be used to treat or metastasize cancer. As an active ingredient of the jeyong pharmaceutical composition may be useful. |
| priorityDate | 2010-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 240.